0000105770-12-000039.txt : 20120620 0000105770-12-000039.hdr.sgml : 20120620 20120620163953 ACCESSION NUMBER: 0000105770-12-000039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120620 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20120620 DATE AS OF CHANGE: 20120620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 12917717 BUSINESS ADDRESS: STREET 1: 101 GORDON DR STREET 2: P O BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 101 GORDON DRIVE STREET 2: PO BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 8-K 1 form8k.htm FORM 8K form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported) – June 20, 2012
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

         
Pennsylvania
  
1-8036
  
23-1210010
(State or other jurisdiction
of Incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
         
101 Gordon Drive, PO Box 645, Lionville, PA
      
19341-0645
(Address of principal executive offices)
      
(Zip Code)
         

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 


Item 7.01.  Regulation FD Disclosure

On June 20, 2012, West Pharmaceutical Services, Inc. issued a press release announcing a technology agreement with Amgen.  A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including the exhibit attached hereto) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01.  Financial Statements and Exhibits

(d)
Exhibits
  
     
 
Exhibit 99.1
West Pharmaceutical Services, Inc. Press Release, dated June 20, 2012.


 
2
 

 

 

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



WEST PHARMACEUTICAL SERVICES, INC.
 
 
/s/ John R. Gailey III
John R. Gailey III, Vice President, General
Counsel and Secretary


 
June 20, 2012
 

 
3
 


 
EXHIBIT INDEX
 
 

 
Exhibit No.
  
Description
99.1
  
West Pharmaceutical Services, Inc. Press Release, dated June 20, 2012.
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

 

  4
 

EX-99.1 2 pressrel.htm PRESS RELEASE pressrel.htm


 

 
Contacts:
West:
 
General/Trade Media:
 
Investors/Financial Media:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
Schwartz MSL
Kristin Villiotte
(781) 684-0770
westpharma@schwartzmsl.com
Westwicke Partners
John Woolford/Stefan Loren
(443) 213-0506/0507
   
West Announces Technology Agreement With Amgen

Lionville, Pennsylvania, June 20, 2012 -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Amgen Inc., a biotechnology pioneer and one of the world’s leading independent biotechnology companies, to evaluate Daikyo Crystal Zenith® technologies for drug containment. These technologies were developed over many years by West’s partner, Daikyo Seiko, Ltd., and are based on a polymeric container, utilizing elastomeric components with Flurotec® barrier film, and  provided in a sterile, validated, ready-to-fill format.
 
“Biopharmaceutical therapeutic products require a drug container that enables safe, effective and reliable containment,” said Donald E. Morel, Jr., Ph.D., West’s Chairman and CEO. “We are delighted to formalize our plan to work with Amgen for evaluating the use of Daikyo Crystal Zenith in commercializing Amgen’s therapeutics.  We value this long-standing relationship and look forward to helping Amgen to meet its objective of advancing science and biotechnology to serve patients.”
 
Martin VanTrieste, Senior Vice President, Quality, Amgen, commented, “Amgen has had a long relationship with West and is excited about strengthening this relationship. As a company that values innovation, we have been impressed with the innovations of West and Daikyo in container-closure systems.”

No further details of the agreement were disclosed.

About West
West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.

Daikyo Crystal Zenith® and Flurotec® are registered trademarks of Daikyo Seiko, Ltd.
Crystal Zenith and Flurotec technologies are licensed from Daikyo Seiko, Ltd.

 
 
 

GRAPHIC 3 westlogo.jpg begin 644 westlogo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`, M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8 M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\? M'Q\?'Q\?'Q\?_\``$0@`9`#=`P$1``(1`0,1`?_$`*8``0`"`P$!`0`````` M```````%!P,&"`0"`0$!``(#`0````````````````0%`0,&`A```@$#`P$$ M!@4)!@0'`````0(#``0%$1(&(3%!$P=187$B%`B!D3(C%:&Q0E*",U.3%M%R MDG-6%V*B51C"0X/#TR14$0`"`0(#!0<$`P$!`````````0(1`Q($!2%189$B M,4&!L5(3(W'!,A3PH171WBV>ASN#MLE'H M'D72>,?H2KT=?K[/50$K0"@%`*`4`H#YEECBB>65@D<:EG=N@"J-23[*RE4P MW0UK_<_R[_U'C_YZ?VUO_4N^ED?]NUZES)3"5R]I976T/X$\JH^UNP MZ$]^E>H9>3$B*"*9&=B`2=`#Z! M699:Y%5<6D8CF;\Z5KA;E-T MBJLV3N1@JR=$0O\`N?Y=_P"H\?\`ST_MK;^I=]+-/[=KU+F;!87]GD+.*\LI MDN+2==\,\9W(Z^E2.T5IE%Q='VF^,E)5789Z\GH4`H!0"@%`"0`23H!U)-`> M?\0L/_TQ?XU_MKUA>X\XEO,D5Q;S:^#*DFW[6Q@VFOITK#31E-,R5@R*`B.3 M\C@P6.-RT3W-P^JVUK&"6D<#7N!T4=YH"DLC=9IS#I;E_Y?D:>&U&JQ?$2-UT^S;2:?\`,16G472S+P\S=IRK?CX^1O?S M1<@UFPW'HV^P'O[A?6VL4/YI*A:1:_*?@3=8N_C#Q*4P&&NLWF['$6H^_OIT M@0Z:A=[`%CZE'4^JK>Y<4(N3[BHM6W.2BN\[CQN/M<=C[;'VB[+:TB2"!/0D M:A5'3U"N/G)R;;[6=C"*BDEV(]%>3T*`4`H!0"@-4\ULO^$^7>>O`=KFU:WC M([0]R1`I'L,FM2^NQ M$IT[8[=!H?\`%*PKG]7G6:CN7F=#I$*0[ M!%UW2/Z``"=/2=.E`4=E[RYY!DY,A>9BU28G[M&^(58T!Z*GW6@`^OOK(,UK MA7U]WE=C$K=ZS7*G7U@Q)0'SD>/1V2+D8^26-U=1R*WW7O( MV!`)QURG7T/$5/YZD915NQ^J(^;=+4OHSBJNN.0+\XAEOZ7^76^R2'96)^WE&^]U_X4($8AB`2%ZL0.@&NG M6KHI"T/EP@\7S(5_X%E/)V:]NU/H^W5=JC^+Q+'2E\W@S7O-SD'X[YA9F[5M MT$,QM;?T>';_`'6H]3%2WTUOR5K!:BO'F:,[=QW9/PY&T>06/QUED,IS3,.( M<7@+8?/F8L M>2Y34G4Z7MP!U]0?2IGZMKTQY(A_M7?5+FS;.#^>W,L)DH$RU[)EL0SJMU%< M_>3*A.A>.4^_N`ZZ,2#^6HN8TZW-=*PR)67U&Y!]3Q1.B><<]PW$>.G,7C>- MXNBV-LA]Z>1AN4*>Y=.K-W#Z!5%E\M*[/"O$OLQF8VH8GX'-')//'S$S4\C1 MY)L7:M^[MK'[G:/\T?>D_M?5706M/M0795\3GKNH79OMHN!`KYA\^5@PY+E- M1U&MY<$?47TK?^K:],>2-'[5WU2YLM7R=\[>17?(;3CO(YA?07S>%:WC@+-' M*02BL5TWJQ]WJ-=>^JS/9""@YPV4+/(ZA-S4)[:FD>9WF3R;.9K,XI\@[X%; MV1;>SVH%V0R$1G4+N_1U[:F93*PA&,J=5"'F\W.BOW7`6D=QTL?PR^AQO75G)EC>867%OP#A/%H3HL5G^*7:#]>Z9FB[AUVNY_:JOR MT*W9SXTY%AFITM0APKS()\(+7RT3+RKI)D\JL5L2.OA6D$F\@^AGGT/]VM_N M5O8=T?-FAVZ6<6^7DB?\ELN,#)RKD&NC6&%E$)_1,TLT0B!]LB@5HS\,>".^ M1OR$\&.>Z)6[,6)9CJQZDGM)J>0"Q.)1],4:!QZ_L,?G+&^R%H+^RMIDDN+-CH)$4Z ME3KJ/H/0U-NQ.8QWE5YJ7&/DQ>9AX_?0(T;V+VT<,TA< M@JO5HUZA,<7^73'X'D./S/XU)=&P MF6=8#`$#,G5?>$ATZ^JM5[5'.#CAI4VV=+4)J6*M"K?/7CO%^/$RS3%I97;34S/(?LJ#]-6.G79S@W)UVE;J-J%N:C%4V&@XRPER&2M+" M']]=S1P1]_O2L$'Y34Z=W M5G4A%61W&KN%[!VUR=[-7+BI)U1UMG*6[;K%497.>RO,.29-KS\/?P(3I;6S MP+(D:G_,4AF.GO&M!(,EGB?,94'P^(B59-"";&R&OHU+1T!,VMMYLH08\1:@ M)T4-%9)I[.JT!,6LOG!&`HL+!`>K%M@^OPY/S4!)PW7FH=3+9XE0.P;Y@?;T M9Z`J6\AY4DBSR8_P7W[HVCM(48,#NU!2,-T]-`7KQ?*S9;`65_/&8IY4(GC8 M;2)(V*/T[@64D5@$I0"@%`*`T'SWE,?E5FR&VL_PR#U[KJ($#]G6ING+YH^/ MD0M1?P2\/-'(==2-8(5`].Q!]-:[<<,?[^ MYLN2Q2_K[%I^>>(3CO#^#\<33?:0W#7&G89=(B[=.GO2.YJMT^?N7)SWT^Y9 M:C#V[=N&ZOV*LL\JUM@\E8)T;(26XD/IBA+N5T_S-A^BK*4*R3W5*V,Z1:WT M)7RTXO\`U-S;%XIUW6S2B6\]'@0^_(#_`'@-OM-:LW>]NVY=YMREGW+BCW'N M\YLJ86D:CL`MT$1'^)2:\9"&&S'GS/>?GBO2YC;CBEV&FS9E$'!?0>&-3MUKS/ M5;>%TK4]0TJYB5:4-]\Z?)N^Y7=)G<'(GXK%$(9[.4[%G5"2I1ST5QKI[W0C MO&G6%D,\K2PR_$G9_(.Z\4?R.I/1AZQTJ^ MMW8S58NI07+4H.DE0CZV&LZ.^6KE^7R=CD\'D)WN8\<(I;*20EF2.32>KP$+H?Y@6O.?GALR MX[#UI\,5Z/#:=<9/'VV1Q]Q87*[H+F-HY!WZ,.T>L=HKECJCG;(8%,=D;JPO MKU(9[:0H1LE;4=H;HO8P((K(,]MB./;U+\B2`Z:EQ;7)T.G=HM`2UKB>.;"1 MSKH3)0&3,?A=GA)Y(N<75Y,_N M1PBY$NN[H=R*7DVZ:ZT!KO#.`OR"^\03@XFW8"YN`KJ6/;X<>X#J1VGN^J@+ MRL[.ULK6*UM8EAMX5"Q1*-``*P#-0"@%`*`K7YAI=GEE>+IKXMQ;)KZ-)`W_ M`(:L-,7S+Q*_4W\+^J.3ZZ8Y@WGR4XZ,YYBXR*1=UM8L;ZX&FHVV^C)J/092 M@J%G[N"T^.PFZ?:QW5PVFX_-%=;N38:UU_=632Z:_P`65E[/_2J+I"Z)/B2M M8?7%<"E:MRH.AOEBXMX5EDN33)H]PWP-FQ_AIH\K#U,^T?LFJ+5KU6H+ZE]I M%FB01W&OC#(W18GOW3,P;]H'6K;+-.W&FY%1F4U2:"TG<+:Q%BI6*-0B:A3H"0NX^LUNRV75NVHOM-.9S#N7 M')=ANOD;BE$/]N[ZGS+*XCYP\6/E[?8[FKS9O*F M25H[6Z1I_&5E'AA9#TCVGO)!':*K[^1G[J=OICP+"QGH>TU"W*;[_L M<[7-Q+VO".07&5N+`W_`(MJ M]LB*XC9"SH^X$AA^AI47.99WHX4Z;25D\RK,L35=AV':2R36L,TL?@R2(KO" M3J49@"5UZ:Z=E;_'X`D.?6W\4KMM[O1BN@U^[L[3]%$9* MX@R."39XV(\73[?_`-B1=WU#I602$&>X6@/B\6\4GL/Q\ZZ?4*P"5AY#P=`K MOP]U51JS>/(X`T_X@`?IH#+B<+8).DBJI?EO\`,9)= MB_`RK_%2W3])%;\E62U6UQ*QZ5>X&P\:^6#(-<))R3*11VX.K6UCN>1A^ MKXDBHJ?X6K1=U=4Z%S)%K2'7K?(O?"X+$X7%0XG&6RV]A;J4CA7J-#U8L3U8 ML3J2>VJ6Y^@%G*Q=;*\+HT>IUV)(B MR;@.[8[2[&%E&NO[QISM_Y49OR5(> MJ6N)&6E7N',W;A_RS65KGMZMI0'MP[>8'+ M;Q+"?)M\!&0;N>%X=J+KKU\`CXM))UNGM4)C6*"4QF8AFU121]G4GH=-=*`R0\F)R302E%@ M^(D@C"HQ8A7CMU);=I^_9QV=@]5`9SRS%^(5C6:5$D$4TJ)JD9:4P*S$D=&D M4@::^GLH#SS, MV]S\5'(8S9^&/%]V-92VF[:%".IU)[].V@,EWG5.&M1(&D*H2S;=2`O:22!VF@/=:YB.ZM;J9()4ELV9)K:10)` MZQK(%T!8>\KJ1H>^@(?'VT<:,L#ATN$=3XR3_$I:QQZ`[?ME]QZ]!K0'SD>706UT8H MHF>*)+J2ZG(U5%M%`<@`ZG1W4&@,G]66$*D70DTB27Q;M(R(&EMD+3I'J2VJ M[6^K376@/K^K+(;D-K="Y5@JVAC'BL#&9=P&[0#8-?>(]';0&D^:N"M+^PLN M3P^(D31HMR5CU;PY!NB=E9DTT+;3[164#2>.<53D&02SQ\TQT&ZXFD@58XE] M)(E;M[AIUH"]\#@L?@\;%C[%-L4?5G/5G<]KL>\FL`D*`4`H!0"@%`*`A\E8 M9A\Q#?V)MR([9[=1.7]QI75F<*H][]VOZ0H"(7@[)>#=\/=0.L(FN;A=TP*2 M/+-LCVE/OFD)U)]W7L-`?IX=D_P^9$NHX[]UM3#.-Q$\C:?1 M0'T>&-%?R/;0VGPX:*2WEE5GF000)&D0!!4+OC#[]=>IZ=]`9FXG<%,=!XJ? M#V5O;6[`Z[F$-?B71(]) M44JKHD";]^@`Z@G2L@G,OQ^YN,=965E(D:V*.(M^H&\6SP0GW0>BL^X^RL`^ M#QF7\5M;@2)\':BV1(NN[P[5)MH[--3+*K>Q:`\*\2RR_%Q>-"8LI%X60EU; MQ$#3S32B(;=&WK<%=21IIWT!]R\3R*S7,\$T;F:ZWI;L[Q(+0EI'BWQJ6!>5 MMS=-"%"]E`8(N&Y-+,6V^V57AN8)MF]5`N[H2R[%V]AC4+IW:5D'HO>'W$\N M0G9HK@SW$4MM;2EEC\)9$FE1V"L09'3K[I^RM8![[;!WMI@IK2S>&TOY9#-O MA39$&+@A>@W$;%";CU[_`%4!X9>.YB3+1YL+:)?))&3:*SB%E2*:/TN9H?A[-F$6TL6E6 M:]QTMA=:RPSQ&*4GM((TU]O?0'DXWQS'\?QB6-FO9[TT MQ`WR/WLVGY/10$I0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`* )`4`H!0"@/__9 ` end